Feasibility and Efficiency of a Novel Bolus Calculator (IF-DIABETE) for Patients With Type 1 Diabetes: A Nonrandomized Single-Arm Pilot Study

被引:1
作者
Rouf, Siham [1 ]
Rbiai, Najwa [1 ]
Baibai, Kaoutar [2 ]
Berrich, Jamal [2 ]
Bouchentouf, Toumi [2 ]
Rahmoun, Mohammed [2 ]
Abda, Naima [3 ]
Latrech, Hanane [1 ]
机构
[1] Mohamed First Univ, Mohammed VI Univ Hosp, Med Sch, Diabetol & Endocrinol, Oujda, Morocco
[2] Mohamed First Univ, Natl Sch Appl Sci, Res Lab Appl Sci, Oujda, Morocco
[3] Mohammed First Univ, Lab Epidemiol Clin Res & Publ Hlth, Oujda, Morocco
关键词
telemedicine; type; 1; diabetes; if-diabete; metabolic control; hypoglycemia; INTENSIFIED INSULIN THERAPY; RANDOMIZED CONTROLLED-TRIAL; GLYCEMIC CONTROL; SELF-CARE; HYPOGLYCEMIA; SYSTEM; MANAGEMENT; EDUCATION; TELECARE; PROGRAM;
D O I
10.7759/cureus.12646
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background The IF-DIABETE system is an insulin bolus dose support, considered as the first bolus calculator dedicated to people with type 1 diabetes, designed in the Arabic language, and adapted to the large Arabic food culture. Our aims were to assess the proof of concept and efficiency of the IF-DIABETE system in improving clinical and metabolic outcomes in individuals with type 1 diabetes. Methods This is a prospective nonrandomized single-arm pilot study. Our patients used the IF-DIABETE smartphone application as a novel bolus calculator. Over six months period of the study, the primary outcome considered was hemoglobin glycated (HbA1c), and we identified hypoglycemic events, body mass index (BMI), and the frequency of blood glucose measurements as secondary outcomes. Results Twenty-one patients with type 1 diabetes were enrolled. The average age was 21 +/- 3 years. Over a six months' period of the study, the mean HbA1c level decreased from 8.3 +/- 0.8% to 7.0 +/- 0.5 % with a reduction in mild hypoglycemic events' frequency from 5 +/- 3 to 1 +/- 0.7 episodes/3 months. We did not observe any change in BMI and the frequency of the blood glucose testing improved from 2 +/- 0.5 to 5 +/- 1 tests per day. Conclusion The IF-DIABETE system was safe and effective to support individuals who have type 1 diabetes to improve their metabolic control. At six months, patients were able to improve their glycemic control without increasing the risk of hypoglycemic events.
引用
收藏
页数:7
相关论文
共 50 条
  • [31] Feasibility and pilot study of an intervention to support active lifestyles in youth with type 1 diabetes: The ActivPals study
    Mitchell, Fiona
    Wilkie, Louise
    Robertson, Kenneth
    Reilly, John J.
    Kirk, Alison
    PEDIATRIC DIABETES, 2018, 19 (03) : 443 - 449
  • [32] Effects of Intensive Exercise on Cognitive Dysfunction in Patients With Pure Cerebellar Degeneration: A Single-Arm Pilot Study
    Shimamoto, Toshiya
    Uchino, Katsuhisa
    Mori, Akira
    Nojima, Kengo
    Iiyama, Junichi
    Misumi, Yohei
    Ueda, Mitsuharu
    Uchino, Makoto
    ANNALS OF REHABILITATION MEDICINE-ARM, 2022, 46 (05): : 263 - 273
  • [33] Canagliflozin Increases Postprandial Total Glucagon-Like Peptide 1 Levels in the Absence of α-Glucosidase Inhibitor Therapy in Patients with Type 2 Diabetes: A Single-Arm, Non-randomized, Open-Label Study
    Osonoi, Takeshi
    Tamasawa, Atsuko
    Osonoi, Yusuke
    Ofuchi, Kensuke
    Katoh, Makoto
    Saito, Miyoko
    DIABETES THERAPY, 2019, 10 (06) : 2045 - 2059
  • [34] Efficacy of scrambler therapy in patients with painful diabetic peripheral neuropathy: A single-arm, prospective, pilot study
    Yoo, Seung Hee
    Kim, Won-joong
    Chae, Ji Seon
    Kang, Bo Kyung
    Kang, Min Jeong
    Beak, Min Hyouk
    MEDICINE, 2023, 102 (39) : E35357
  • [35] Continuous Glucose Monitoring During Basal-Bolus Therapy Using Insulin Glargine 300 U mL-1 and Glargine 100 U mL-1 in Japanese People with Type 1 Diabetes Mellitus: A Crossover Pilot Study
    Jinnouchi, Hideaki
    Koyama, Masayoshi
    Amano, Atsushi
    Takahashi, Yoshinori
    Yoshida, Akira
    Hieshima, Kunio
    Sugiyama, Seigo
    Kurinami, Noboru
    Jinnouchi, Tomio
    Becker, Reinhard
    DIABETES THERAPY, 2015, 6 (02) : 143 - 152
  • [36] Efficacy and safety of dosage-escalation of low-dosage esaxerenone added to a RAS inhibitor in hypertensive patients with type 2 diabetes and albuminuria: a single-arm, open-label study
    Itoh, Hiroshi
    Ito, Sadayoshi
    Rakugi, Hiromi
    Okuda, Yasuyuki
    Nishioka, Satoshi
    HYPERTENSION RESEARCH, 2019, 42 (10) : 1572 - 1581
  • [37] Use of a decision support tool and quick start onboarding tool in individuals with type 1 diabetes using advanced automated insulin delivery: a single-arm multi-phase intervention study
    Sehgal, Shekhar
    De Bock, Martin
    Grosman, Benyamin
    Williman, Jonathan
    Kurtz, Natalie
    Guzman, Vanessa
    Benedetti, Andrea
    Roy, Anirban
    Turksoy, Kamuran
    Juarez, Magaly
    Jones, Shirley
    Frewen, Carla
    Watson, Antony
    Taylor, Barry
    Wheeler, Benjamin J.
    BMC ENDOCRINE DISORDERS, 2024, 24 (01)
  • [38] Outcomes of using flash glucose monitoring technology by children and young people with type 1 diabetes in a single arm study
    Campbell, Fiona M.
    Murphy, Nuala P.
    Stewart, Caroline
    Biester, Torben
    Kordonouri, Olga
    PEDIATRIC DIABETES, 2018, 19 (07) : 1294 - 1301
  • [39] Continuous Glucose Monitoring Among Patients With Type 1 Diabetes in Rwanda (CAPT1D) Phase I: Prospective Observational Feasibility Study
    Baker, Jason
    Cappon, Giacomo
    Habineza, Jean Claude
    Basch, Corey H.
    Mey, Steven
    Malkin-Washeim, Diana L.
    Schuetz, Christian
    Pierre, Niyonsenga Simon
    Uwingabire, Etienne
    Mukamazimpaka, Alvera
    Mbonyi, Paul
    Narayanan, Sandhya
    JMIR FORMATIVE RESEARCH, 2025, 9
  • [40] A pilot randomised controlled parallel arm trial evaluating treatment satisfaction with the Omnipod DASH® Insulin Management System compared with usual care in adults with type 1 diabetes in Australia: rationale, study design and methodologies
    Kong, Yee Wen
    Yuan, Cheng Yi
    Kiburg, Katerina
    Brown, Katrin
    Trawley, Steven
    Partovi, Andi
    Roem, Kerryn
    Harrison, Natalie
    Fourlanos, Spiros
    Ekinci, Elif I.
    ONeal, David N.
    PILOT AND FEASIBILITY STUDIES, 2023, 9 (01)